<DOC>
	<DOC>NCT02552667</DOC>
	<brief_summary>Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.</brief_summary>
	<brief_title>Efficacy and Safety of HCP1102 Capsule</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Inclusion: Ageâ‰¥15 Mild or moderate asthma patients with allergic rhinitis Patient who meet all criteria of rhinitis Patients understood the contents and purpose of this trial and signed informed consent form Patients who are capable and willing to write subject diary Patients who agree with maintain same environment during clinical trials Exclusion: Nonallergic rhinitis Severe asthma Other pulmonary disease (pulmonary tuberculosis, COPD) except Asthma Medical history of hypertrophic cardiomyopathy, cancer, renal disease, Liver disease, cardiovascular disease, respiratory disease, endocrine disorder, CNS disorder that effect safety Medical history of gastrointestinal surgery or gastrointestinal disorders that effect drug absorption Alcohol abuse or Drug abuse Genetic factor of galactose intolerance or Lapp lactase deficiency or glucosegalactose malabsorption pregnant or breastfeeding women or men/women of childbearing age that they don't use contraceptives Patient who administered other investigational products within 30 days Current smoker Judged to be inappropriate for the study by the investigator after reviewing other reasons</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic rhinitis</keyword>
</DOC>